News | December 25, 2025
Jacobio Pharma partners with AstraZeneca in $2 billion licensing deal for pan-KRAS inhibitor
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
Company acquires People Tree Hospital Yeshwanthpur for Rs. 430 crore
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Subscribe To Our Newsletter & Stay Updated
